Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
EpimAb Biotherapeutics, Inc. on 4 September out-licensed to Vignette Bio development and commercialization rights outside of Greater China to the BCMAxCD3-targeting T-cell engager EMB-06 in autoimmune diseases
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
